Clinical Trial Updates (SCD)
-
Ferriprox® (deferiprone)
Update: 31 March 2023 No update available. Update: 20 December 2022 No update available. Update: 30 September 2022 No update available. Update: 30 June 2022 No…
Weiterlesen » -
L-Glutamine
Update: 31 March 2023 No update available. Update: 20 December 2022 – The Qatar Ministry of Public Health has granted marketing authorization for the commercial distribution and sale…
Weiterlesen » -
Mitapivat
Update: 31 March 2023 Completed enrollment in the Phase 2 portion of the RISE UP study of PYRUKYND® in adults with sickle cell disease. Anticipate to announce data and…
Weiterlesen » -
FT-4202
Update: 31 March 2023 No update available. Update: 20 December 2022 No update available. Update: 30 September 2022 No update available. Update: 30 June 2022 The…
Weiterlesen » -
FTX-6058
Update: 31 March 2023 FTX-6058 is a small molecule designed to increase fetal haemoglobin. FTX-6058 is being developed for the treatment of sickle cell disease (SCD) and other hemoglobinopathies.…
Weiterlesen » -
Adakveo (crizanlizumab)
Update: 31 March 2023 Preliminary results from the ongoing global Phase III STAND study in sickle cell disease showed no difference between Adakveo and placebo in annual rates of…
Weiterlesen » -
Oxbryta (voxelotor)
Update: 31 March 2023 Preliminary draft guidance from England’s HTA body NICE states the product is not an acceptable use of National Health Service resources. Previously the UK regulatory…
Weiterlesen »